Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Leveraging Vulnerabilities of Molecular Subtypes to Identify Rational Combination Therapies-The Next Wave in Extensive-Stage SCLC?

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

The future promise of antibody-drug conjugates in extensive-stage small cell lung cancer.

Cancer·2026
Same author

High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.

Clinical lung cancer·2026

相关实验视频

Updated: Sep 12, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

小细胞肺癌的最新情况

Yunan Nie1, Anne C Chiang1

  • 1Division of Thoracic Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut.

Seminars in respiratory and critical care medicine
|August 7, 2025
PubMed
概括

小细胞肺癌 (SCLC) 治疗正在迅速发展,有新的化疗免疫疗法选择. 尽管生存率有所改善,但大多数患者仍然面临疾病进展,这凸显了对更好的治疗方法的持续需求.

科学领域:

  • 在瘤学瘤学.
  • 肺部病理学 肺部病理学
  • 医学瘤学 医学瘤学

背景情况:

  • 小细胞肺癌 (SCLC) 是一种侵略性的神经内分泌瘤,预后不佳,治疗选择有限.
  • 晚期SCLC,诊断在70%的患者中,历史上5年生存率低于5%.
  • 治疗耐药性和早期转移是SCLC的标志,这有助于其具有挑战性的性质.

研究的目的:

  • 审查目前对SCLC的护理标准.
  • 突出最近在SCLC治疗方面的进展和有前途的临床试验.
  • 讨论SCLC患者的治疗结果和生存率的改善.

主要方法:

  • 审查最近的SCLC临床试验和治疗批准.
  • 分析一线,二线和整合性治疗策略.
  • 专注于免疫疗法和新药在SCLC治疗中的影响.

主要成果:

  • 晚期SCLC的第一线治疗现在结合了化疗和免疫疗法.
  • 化学辐射治疗后的巩固性免疫疗法显著改善了早期SCLC的存活率.
  • 最近的试验显示,使用化疗免疫治疗的高级SCLC的3年生存率为16-17% .

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

相关实验视频

Last Updated: Sep 12, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K

结论:

  • 由于新的批准和改善的生存率,SCLC治疗已经取得了重大进展.
  • 尽管取得了进展,但在一线治疗后疾病的快速进展仍然是一个挑战.
  • 进一步的研究对于解决SCLC管理中未得到满足的需求至关重要.